NEW YORK (GenomeWeb News) - Qiagen said today it will buy the sample-separation technology company eGene in a cash and stock deal valued at around $34 million.
 
Qiagen offered $.65 cash and .0416 of its common shares for each share of eGene’s stock.
 
eGene, which is based in Irvine, Calif., sells the HAD-GT12 Genetic Analyzer, a multi-channel sample separation and analysis solution that includes software and a range of consumable cartridges.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.